for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Insmed Incorporated

INSM.OQ

Latest Trade

22.89USD

Change

0.08(+0.35%)

Volume

47,769

Today's Range

22.76

 - 

23.44

52 Week Range

11.31

 - 

33.09

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
22.81
Open
22.79
Volume
47,769
3M AVG Volume
23.18
Today's High
23.44
Today's Low
22.76
52 Week High
33.09
52 Week Low
11.31
Shares Out (MIL)
89.34
Market Cap (MIL)
2,080.82
Forward P/E
-7.88
Dividend (Yield %)
--

Next Event

Q4 2019 Insmed Inc Earnings Release

Latest Developments

More

Insmed Reports Q3 Gaap Loss Per Share $0.68

Insmed Reports Second Quarter 2019 Financial Results And Provides Business Update

Insmed Announces Closing Of Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Insmed Incorporated

Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Industry

Biotechnology & Drugs

Contact Info

700 US Highway 202/206

+1.908.9779900

http://www.insmed.com/

Executive Leadership

William H. Lewis

Chairman of the Board, President, Chief Executive Officer

Roger Adsett

Chief Operating Officer

John R Goll

Chief Accounting Officer

John Soriano

Chief Compliance Officer

Christine A. Pellizzari

Chief Legal Officer

Key Stats

1.78 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

-2.850

2017

-2.890

2018

-4.220

2019(E)

-2.955
Price To Earnings (TTM)
--
Price To Sales (TTM)
20.69
Price To Book (MRQ)
6.84
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
108.87
LT Debt To Equity (MRQ)
108.87
Return on Investment (TTM)
-45.70
Return on Equity (TTM)
-41.12

Latest News

Latest News

Insmed's treatment-resistant lung disease drug gets FDA approval

The U.S. Food and Drug Administration on Friday approved Insmed Inc's lead drug to treat a rare, chronic lung disease, making it the first approved treatment in the United States for the condition.

Insmed's treatment-resistant lung disease drug gets FDA approval

The U.S. Food and Drug Administration on Friday approved Insmed Inc's lead drug to treat a rare, chronic lung disease, making it the first approved treatment in the United States for the condition.

BRIEF-Insmed Announces FDA Acceptance For Filing Of NDA For Lung Disease Treatment

* INSMED ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR ALIS IN NTM LUNG DISEASE CAUSED BY MAC

BRIEF-Insmed Reports Q1 Loss Per Share $0.89

* INSMED REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Insmed Inc Submits NDA To FDA For ALIS

* INSMED SUBMITS NEW DRUG APPLICATION TO FDA FOR ALIS IN NTM LUNG DISEASE CAUSED BY MAC

BRIEF-Insmed Reports Q4 Loss Per Share $0.85

* INSMED REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Insmed Prices Public Offering Of $400 Mln Principal Amount Of Its Convertible Senior Notes

* INSMED ANNOUNCES PRICING OF PUBLIC OFFERING OF CONVERTIBLE SENIOR NOTES

BRIEF-Insmed Announces Proposed Public Offering Of Convertible Senior Notes

* INSMED ANNOUNCES PROPOSED PUBLIC OFFERING OF CONVERTIBLE SENIOR NOTES

BRIEF-Insmed Q3 loss per share $0.69

* Insmed reports third quarter 2017 financial results and provides business update

BRIEF-Arsanis appoints Michael Gray as chief financial officer

* Arsanis announces appointments of Chip Clark and David Mcgirr to board of directors and promotion of Michael Gray to chief operating officer and chief financial officer Source text for Eikon: Further company coverage:

BRIEF-Insmed announces proposed public offering of common stock

* Insmed Inc - Has commenced an underwritten public offering of $250 million of shares of its common stock

Insmed shares skyrocket after lung drug meets key study's main goal

Shares of Insmed Inc more than doubled on Tuesday after the company said its drug to treat adults with a rare lung disorder met the main goal in a key study, leading it to apply for accelerated approval.

Insmed's lung drug meets main goal in late-stage study

Insmed Inc said its drug for the treatment of a rare and serious lung disorder met the main goal in a late-stage study, sending its shares up 75 percent in premarket trading on Tuesday.

BRIEF-Insmed announces positive top-line results from phase 3 convert study of ALIS

* Insmed announces positive top-line results from phase 3 convert study of ALIS (amikacin liposome inhalation suspension) in adult patients with treatment-refractory nontuberculous mycobacterial (NTM) lung disease caused by mycobacterium avium complex (MAC)

BRIEF-Insmed reports Q2 loss per share $0.72

* Insmed reports second quarter 2017 financial results and provides business update

BRIEF-Insmed Inc files for potential stock shelf offering

* Files for potential stock shelf offering; size not disclosed - SEC filing Source text for Eikon: (http://bit.ly/2r15Mrb) Further company coverage:

BRIEF-Insmed appoints Paolo Tombesi CFO, effective June 1, 2017

* Insmed announces key additions to its executive management team

BRIEF-Insmed reports Q1 loss per share $0.60

* Insmed reports first quarter 2017 financial results and provides business update

BRIEF-Insmed extends Arikayce intellectual property protection with issuance of new US patent

* Extends Arikayce intellectual property protection with issuance of new U.S. Patent Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up